(Q48618784)

13 February 2018

title

Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors (English)

1 reference

13 February 2018

author name string

Miguel A Ortega

1

1 reference

13 February 2018

María E Montoya

2

1 reference

13 February 2018

Belén Zarranz

3

1 reference

13 February 2018

Andrés Jaso

4

1 reference

13 February 2018

Ignacio Aldana

5

1 reference

13 February 2018

Sophie Leclerc

6

1 reference

13 February 2018

Laurent Meijer

7

1 reference

13 February 2018

Antonio Monge

8

1 reference

13 February 2018

language of work or name

English

0 references

publication date

1 July 2002

1 reference

13 February 2018

Bioorganic & Medicinal Chemistry

published in

1 reference

13 February 2018

volume

10

1 reference

13 February 2018

issue

7

1 reference

13 February 2018

page(s)

2177-2184

1 reference

13 February 2018

Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Molecular foundations of cancer: New targets for intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

CDK inhibition and cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Chemical inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Chemical inhibitors of cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Cyclin-dependent kinase inhibitors: novel anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Cyclin-dependent kinases: engines, clocks, and microprocessors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Activity and regulation of p35/Cdk5 kinase complex

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Inhibition of cyclin-dependent kinases by purine analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

Baculovirus-mediated expression and characterisation of rat glycogen synthase kinase-3 beta, the mammalian homologue of the Drosophila melanogaster zeste-white 3sgg homeotic gene product

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900069-X

7 January 2021

10.1016/S0968-0896(02)00069-X

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vluofxqayfecdk6t2jo3o2ilgy

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_vluofxqayfecdk6t2jo3o2ilgy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vluofxqayfecdk6t2jo3o2ilgy

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/vluofxqayfecdk6t2jo3o2ilgy

1 reference

30 July 2022